drugset / Trial / NCT03758885

Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF

NCT03758885 ↗

Phase 3 Completed 820 enrolled ObsEva SA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to confirm the efficacy of a single oral 900 mg dose of nolasiban versus placebo to increase the ongoing clinical pregnancy rate at 10 weeks post-embryo transfer (ET) day.

Timeline

Start
2019-01-10
Primary completion
2019-11-21
Completion
2020-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Nolasiban Small molecule 900 mg Oral

Indications